Aldevron Breakthrough Blog

Forum Report: Aldevron's expansion could equate to $500 million for region

News report courtesy Forum Communication, written by Barry Amundson. Published August 29, 2019

Tax incentive supporters are putting the pressure on to show that programs being offered to businesses and developers are not only going to eventually provide impressive property tax payments but also provide positive ripple effects in the community.

Read More

Aldevron capacity, capability growth key to gene, cell and protein therapeutics research

0319-GEN-logoAldevron is "Driven by a Passion to Enable Science," as featured in the April Genetic Engineering & Biotechnology News. This article spans our new production facility in Fargo, North Dakota, and the expansion of our Freiburg, Germany, antibody facility, to our expanding CRISPR options, the publication discusses our ongoing push to help researchers in their work.

One particular highlight is the discussion of our new CRISPR options, including GMP level SpyFiTM Cas9 Nuclease and the availability of in-stock GMP level prepacked CRISPR nucleases.

Read More

A successful and inspiring Breakthrough Symposium

Earlier this month Aldevron hosted its first scientific conference, the Breakthrough Symposium. We felt the time was right, given 2018 is Aldevron’s 20th anniversary, to invite those in the gene and cell therapy fields to Fargo, North Dakota, for collaboration, networking and fellowship. We were overwhelmed and gratified by the response!

Read More

Aldevron Honored by Goldman Sachs for Entrepreneurship

Michael Chambers, Founder and CEO, Among 100 Most Intriguing Entrepreneurs at 2018 Builders + Innovators Summit

Goldman Sachs (NYSE:GS) is recognizing Aldevron CEO and Founder Michael Chambers as one of the 100 Most Intriguing Entrepreneurs at the 2018 Builders + Innovators Summit in Santa Barbara, California.

Read More